Report cover image

Companion Diagnostics for Oncology Market

Publisher Evolve Business Intelligence
Published Apr 14, 2025
SKU # EVBI19932380

Description

The global Companion Diagnostics for Oncology market is projected to reach $6.18 billion by 2028, expanding at a compound annual growth rate (CAGR) of 18.65% from 2021 to 2028. This growth is driven by various macroeconomic and microeconomic factors, including the rising number of cancer tests, which significantly contributes to the increasing demand for companion diagnostics in oncology.

The latest research report by Evolve Business Intelligence explores the various factors influencing the global market. It includes an analysis of the current market size, forecasts for key segments and regions, and the driving forces behind market growth. The report examines the potential impacts of key trends on business strategies and provides a SWOT analysis of critical sectors for each major competitor and customer group. This valuable data highlights the conglomerates likely to impact the industry, crucial for any company planning to invest strategically over the next five years. These insights complement our initial quantitative study, aiding in new investments and strategic planning to mitigate threats in existing sectors.

Segments covered

By Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH), Fluorescence in situ hybridization (FISH), Others)
By Disease Type (Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Leukemia, Melanoma, Others)
By End-user (Hospital, Pathology/Diagnostic Laboratory, Academic Medical Center, Others)

Key players

Agilent Technologies, Inc
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
Hoffmann-La Roche Ltd.
ARUP Laboratories
Abbott
Myriad Genetics, Inc.
bioMérieux SA
Illumina, Inc.
Invivoscribe, Inc.

Table of Contents

Chapter 1. Executive Summary
Chapter 2. Scope of The Study
2.1. Market Definition
2.2. Scope of The Study
2.2.1. Objectives of Report
Chapter 3. Evolve BI Methodology
Chapter 4. Market Insights and Trends
4.1. Supply/ Value Chain Analysis
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Threat of Substitutes
4.2.5. Industry Rivalry
4.3. Impact of COVID-19 on Companion Diagnostics for Oncology Market
4.3.1. Impact on Market Size
4.3.2. End User Trend, Preferences and Budget Impact
4.3.3. Regulatory Framework/Government Policies
4.3.4. Key Players Strategy to Tackle Negative Impact
4.3.5. Opportunity Window
Chapter 5. Market Dynamics
5.1. Introduction
5.2. DRO Analysis
5.2.1. Drivers
5.2.2. Restraints
5.2.3. Opportunities
Chapter 6. Global Companion Diagnostics for Oncology Market, By Technology
6.1. Introduction
6.2. Polymerase Chain Reaction (PCR)
6.3. Next-Generation Sequencing (NGS)
6.3. Immunohistochemistry (IHC)
6.4. In situ hybridization (ISH)
6.5. Fluorescence in situ hybridization (FISH)
6.6. Others
Chapter 7. Global Companion Diagnostics for Oncology Market, By Disease Type
7.1. Introduction
7.2. Breast Cancer
7.3. Non-Small Cell Lung Cancer
7.4. Colorectal Cancer
7.5. Leukemia
7.6. Melanoma
7.7. Others
Chapter 8. Global Companion Diagnostics for Oncology Market, By End-user
8.1. Introduction
8.2. Hospital
8.3. Pathology/Diagnostic Laboratory
8.4. Academic Medical Center
8.5. Others
Chapter 9. Global Companion Diagnostics for Oncology Market, By Region
9.1. Introduction
9.2. North America
9.2.1. Introduction
9.2.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.3. Market Size and Forecast, By Country, 2020 - 2028
9.2.4. Market Size and Forecast, By Technology, 2020 - 2028
9.2.5. Market Size and Forecast, By Disease Type, 2020 – 2028
9.2.6. Market Size and Forecast, By End-user, 2020 – 2028
9.2.7. US
9.2.7.1. Introduction
9.2.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.7.3. Market Size and Forecast, By Technology, 2020 - 2028
9.2.7.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.2.7.5. Market Size and Forecast, By End-user, 2020 - 2028
9.2.8. Canada
9.2.8.1. Introduction
9.2.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.2.8.4. Market Size and Forecast, By Technology, 2020 - 2028
9.2.8.5. Market Size and Forecast, By Disease Type, 2020 – 2028
9.2.8.6. Market Size and Forecast, By End-user, 2020 - 2028
9.3. Europe
9.3.1. Introduction
9.3.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.3. Market Size and Forecast, By Country, 2020 - 2028
9.3.4. Market Size and Forecast, By Technology, 2020 - 2028
9.3.5. Market Size and Forecast, By Disease Type, 2020 – 2028
9.3.6. Market Size and Forecast, By End-user, 2020 – 2028
9.3.7. Germany
9.3.7.1. Introduction
9.3.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.7.3. Market Size and Forecast, By Technology, 2020 - 2028
9.3.7.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.3.7.5. Market Size and Forecast, By End-user, 2020 - 2028
9.3.8. France
9.3.8.1. Introduction
9.3.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.8.3. Market Size and Forecast, By Technology, 2020 - 2028
9.3.8.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.3.8.5. Market Size and Forecast, By End-user, 2020 - 2028
9.3.9. UK
9.3.9.1. Introduction
9.3.9.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.9.3. Market Size and Forecast, By Technology, 2020 - 2028
9.3.9.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.3.9.5. Market Size and Forecast, By End-user, 2020 - 2028
9.3.10. Italy
9.3.10.1. Introduction
9.3.10.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.10.3. Market Size and Forecast, By Technology, 2020 - 2028
9.3.10.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.3.10.5. Market Size and Forecast, By End-user, 2020 - 2028
9.3.11. Rest of Europe
9.3.11.1. Introduction
9.3.11.2. Driving Factors, Opportunity Analyzed and Key Trends
9.3.11.3. Market Size and Forecast, By Technology, 2020 - 2028
9.3.11.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.3.11.5. Market Size and Forecast, By End-user, 2020 - 2028
9.4. Asia-Pacific
9.4.1. Introduction
9.4.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.3. Market Size and Forecast, By Country, 2020 - 2028
9.4.4. Market Size and Forecast, By Technology, 2020 - 2028
9.4.5. Market Size and Forecast, By Disease Type, 2020 – 2028
9.4.7. Market Size and Forecast, By End-user, 2020 - 2028
9.4.8. China
9.4.8.1. Introduction
9.4.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.8.3. Market Size and Forecast, By Technology, 2020 - 2028
9.4.8.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.4.8.5. Market Size and Forecast, By End-user, 2020 - 2028
9.4.9. India
9.4.9.1. Introduction
9.4.9.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.9.3. Market Size and Forecast, By Technology, 2020 - 2028
9.4.9.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.4.9.5. Market Size and Forecast, By End-user, 2020 - 2028
9.4.10. Japan
9.4.10.1. Introduction
9.4.10.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.10.3. Market Size and Forecast, By Technology, 2020 - 2028
9.4.10.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.4.10.5. Market Size and Forecast, By End-user, 2020 - 2028
9.4.11. South Korea
9.4.11.1. Introduction
9.4.11.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.11.3. Market Size and Forecast, By Technology, 2020 - 2028
9.4.11.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.4.11.5. Market Size and Forecast, By End-user, 2020 - 2028
9.4.12. Rest of Asia-Pacific
9.4.11.1. Introduction
9.4.12.2. Driving Factors, Opportunity Analyzed and Key Trends
9.4.12.3. Market Size and Forecast, By Technology, 2020 - 2028
9.4.12.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.4.12.5. Market Size and Forecast, By End-user, 2020 - 2028
9.5. Rest of The World (RoW)
9.5.1. Introduction
9.5.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.3. Market Size and Forecast, By Technology, 2020 - 2028
9.5.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.5.5. Market Size and Forecast, By End-user, 2020 - 2028
9.5.6. Market Size and Forecast, By Region, 2020 - 2028
9.5.7. South America
9.5.7.1. Introduction
9.5.7.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.7.3. Market Size and Forecast, By Technology, 2020 - 2028
9.5.7.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.5.7.5. Market Size and Forecast, By End-user, 2020 - 2028
9.5.8. Middle East & Africa
9.5.8.1. Introduction
9.5.8.2. Driving Factors, Opportunity Analyzed and Key Trends
9.5.8.3. Market Size and Forecast, By Technology, 2020 - 2028
9.5.8.4. Market Size and Forecast, By Disease Type, 2020 – 2028
9.5.8.5. Market Size and Forecast, By End-user, 2020 - 2028
Chapter 10. Competitive Landscape
10.1. Introduction
10.2. Vendor Share Analysis, 2020/Key Players Positioning 2020
Chapter 11. Company Profiles
11.1. Agilent Technologies, Inc
11.1.1. Business Overview
11.1.2. Financial Analysis
11.1.3. Product Portfolio
11.1.4. Recent Development and Strategies Adopted
11.1.5. SWOT Analysis
11.2. QIAGEN N.V.
11.2.1. Business Overview
11.2.2. Financial Analysis
11.2.3. Product Portfolio
11.2.4. Recent Development and Strategies Adopted
11.2.5. SWOT Analysis
11.3. Thermo Fisher Scientific, Inc.
11.3.1. Business Overview
11.3.2. Financial Analysis
11.3.3. Product Portfolio
11.3.4. Recent Development and Strategies Adopted
11.3.5. SWOT Analysis
11.4. F. Hoffmann-La Roche Ltd.
11.4.1. Business Overview
11.4.2. Financial Analysis
11.4.3. Product Portfolio
11.4.4. Recent Development and Strategies Adopted
11.4.5. SWOT Analysis
11.5. ARUP Laboratories
11.5.1. Business Overview
11.5.2. Financial Analysis
11.5.3. Product Portfolio
11.5.4. Recent Development and Strategies Adopted
11.5.5. SWOT Analysis
11.6. Abbott
11.6.1. Business Overview
11.6.2. Financial Analysis
11.6.3. Product Portfolio
11.6.4. Recent Development and Strategies Adopted
11.6.5. SWOT Analysis
11.7. Myriad Genetics, Inc.
11.7.1. Business Overview
11.7.2. Financial Analysis
11.7.3. Product Portfolio
11.7.4. Recent Development and Strategies Adopted
11.7.5. SWOT Analysis
11.8. bioMérieux SA
11.8.1. Business Overview
11.8.2. Financial Analysis
11.8.3. Product Portfolio
11.8.4. Recent Development and Strategies Adopted
11.8.5. SWOT Analysis
11.9. Illumina, Inc.
11.9.1. Business Overview
11.9.2. Financial Analysis
11.9.3. Product Portfolio
11.9.4. Recent Development and Strategies Adopted
11.9.5. SWOT Analysis
11.10. Invivoscribe, Inc.
11.10.1. Business Overview
11.10.2. Financial Analysis
11.10.3. Product Portfolio
11.9.4. Recent Development and Strategies Adopted
11.9.5. SWOT Analysis
Chapter 12. Key Takeaways

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us